Target
Serine/threonine-protein kinase PLK2
Ligand
BDBM50436733
Substrate
n/a
Meas. Tech.
ChEMBL_971578 (CHEMBL2406852)
IC50
120±n/a nM
Citation
 Bowers, STruong, APYe, MAubele, DLSealy, JMNeitz, RJHom, RKChan, WDappen, MSGalemmo, RAKonradi, AWSham, HLZhu, YLBeroza, PTonn, GZhang, HHoffman, JMotter, RFauss, DTanaka, PBova, MPRen, ZTam, DRuslim, LBaker, JPandya, DDiep, LFitzgerald, KArtis, DRAnderson, JPBergeron, M Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors. Bioorg Med Chem Lett 23:2743-9 (2013) [PubMed]  Article 
Target
Name:
Serine/threonine-protein kinase PLK2
Synonyms:
PLK2 | PLK2_HUMAN | Polo-Like Kinase 2 | SNK | Serine/threonine-protein kinase PLK2 | Serine/threonine-protein kinase SNK | Serum-inducible kinase
Type:
Serine/threonine-protein kinase
Mol. Mass.:
78259.87
Organism:
Homo sapiens (Human)
Description:
Full-length human PLK2 was expressed as GST-fusion protein using baculovirus expression system. GST-PLK2 was purified by using glutathione sepharose chromatography.
Residue:
685
Sequence:
MELLRTITYQPAASTKMCEQALGKGCGADSKKKRPPQPPEESQPPQSQAQVPPAAPHHHHHHSHSGPEISRIIVDPTTGKRYCRGKVLGKGGFAKCYEMTDLTNNKVYAAKIIPHSRVAKPHQREKIDKEIELHRILHHKHVVQFYHYFEDKENIYILLEYCSRRSMAHILKARKVLTEPEVRYYLRQIVSGLKYLHEQEILHRDLKLGNFFINEAMELKVGDFGLAARLEPLEHRRRTICGTPNYLSPEVLNKQGHGCESDIWALGCVMYTMLLGRPPFETTNLKETYRCIREARYTMPSSLLAPAKHLIASMLSKNPEDRPSLDDIIRHDFFLQGFTPDRLSSSCCHTVPDFHLSSPAKNFFKKAAAALFGGKKDKARYIDTHNRVSKEDEDIYKLRHDLKKTSITQQPSKHRTDEELQPPTTTVARSGTPAVENKQQIGDAIRMIVRGTLGSCSSSSECLEDSTMGSVADTVARVLRGCLENMPEADCIPKEQLSTSFQWVTKWVDYSNKYGFGYQLSDHTVGVLFNNGAHMSLLPDKKTVHYYAELGQCSVFPATDAPEQFISQVTVLKYFSHYMEENLMDGGDLPSVTDIRRPRLYLLQWLKSDKALMMLFNDGTFQVNFYHDHTKIIICSQNEEYLLTYINEDRISTTFRLTTLLMSGCSSELKNRMEYALNMLLQRCN
  
Inhibitor
Name:
BDBM50436733
Synonyms:
CHEMBL2401958
Type:
Small organic molecule
Emp. Form.:
C21H17F7N6O
Mol. Mass.:
502.3881
SMILES:
CN1C(=O)C(CC(F)(F)F)N(CCC(F)(F)F)c2nc(ncc12)-n1ccnc1-c1ccc(F)cc1
Structure:
Search PDB for entries with ligand similarity: